angiogenesis inhibitor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for angiogenesis inhibitor, covering 2026-03-16 to 2026-03-16. Get the full timeline:
Most recent: Clinical Trial Update: PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer [Phase 2, Phase 3]